BlackRock Institutional Trust’s Coherus Oncology CHRS Stock Holding History

BlackRock Institutional Trust’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$20.8M	Buy	740,118 +24,643	+3%	+$690K	﹤0.01%	1932
2016 Q3	$19.2M	Buy	715,475 +240,482	+51%	+$6.56M	﹤0.01%	1923
2016 Q2	$8.02M	Buy	474,993 +84,738	+22%	+$1.59M	﹤0.01%	2423
2016 Q1	$8.29M	Buy	390,255 +2,025	+0.5%	+$33.2K	﹤0.01%	2385
2015 Q4	$8.91M	Buy	388,230 +13,120	+3%	+$338K	﹤0.01%	2399
2015 Q3	$7.52M	Buy	375,110 +159,729	+74%	+$4.86M	﹤0.01%	2480
2015 Q2	$5.17M	Buy	+215,381	New	+$5.44M	﹤0.01%	2754

Other funds holding CHRS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BlackRock Institutional Trust's CHRS Position: Q4 2016 in Review

BlackRock Institutional Trust increased its Coherus Oncology (CHRS) stake by 3.4% in Q4 2016, buying an estimated $690K and bringing the position to 740,118 shares worth $20.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1932.

BlackRock Institutional Trust first reported a position in CHRS in Q2 2015 and has held it in 7 quarters since. 122 funds tracked by Wall St. Rank hold CHRS as of Q4 2016.

BlackRock Institutional Trust held 740,118 shares of Coherus Oncology worth $20.8M as of Q4 2016.
BlackRock Institutional Trust bought 24,643 Coherus Oncology shares in Q4 2016, an estimated $690K.
Coherus Oncology made up ﹤0.01% of BlackRock Institutional Trust's portfolio in Q4 2016, its #1932 holding.
BlackRock Institutional Trust first reported a position in Coherus Oncology in Q2 2015 and has held it in 7 quarters since.
122 funds tracked by Wall St. Rank held Coherus Oncology as of Q4 2016.

Based on BlackRock Institutional Trust's 13F filing for Q4 2016, filed 10 Feb 2017.